Risk and Management of Patients with Cancer and Heart Disease

Overview

Journal Cardiol Ther

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 9

PMID 36757637

Authors

Loreena Hill

Bruno Delgado

Ekaterini Lambrinou

Tara Mannion

Mark Harbinson

Claire McCune

Affiliations

Soon will be listed here.

Abstract

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

References

Daugaard G, Lassen U, Bie P, Pedersen E, Jensen K, Abildgaard U . Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005; 7(1):87-93. DOI: 10.1016/j.ejheart.2004.03.009. View

Andres M, Pan J, Lyon A . What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. Clin Oncol (R Coll Radiol). 2021; 33(8):483-493. DOI: 10.1016/j.clon.2021.03.012. View

Sadler D, Arnold A, Herrmann J, Daniele A, Silva C, Ghosh A . Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building. Curr Oncol Rep. 2021; 23(6):64. PMC: 8045572. DOI: 10.1007/s11912-021-01059-1. View

Hojan K, Procyk D, Horynska-Kestowicz D, Leporowska E, Litwiniuk M . The Preventive role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy-An REH-HER Study. J Clin Med. 2020; 9(5). PMC: 7291322. DOI: 10.3390/jcm9051379. View

Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16(3):e123-36. PMC: 4485458. DOI: 10.1016/S1470-2045(14)70409-7. View

Diaz-Gavela A, Figueiras-Graillet L, Montero Luis A, Salas Segura J, Ciervide R, Cerro Penalver E . Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies. Cancers (Basel). 2021; 13(7). PMC: 8038596. DOI: 10.3390/cancers13071712. View

White J, Byles J, Williams T, Untaru R, Ngo D, Sverdlov A . Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences. Cardiooncology. 2022; 8(1):14. PMC: 9364611. DOI: 10.1186/s40959-022-00140-3. View

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

10.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

11.

Okwuosa T, Ray R, Palomo A, Foraker R, Johnson L, Paskett E . Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast Cancer: Women's Health Initiative. JACC CardioOncol. 2021; 1(1):41-50. PMC: 8352124. DOI: 10.1016/j.jaccao.2019.08.014. View

12.

Chen Y, Chow E, Oeffinger K, Border W, Leisenring W, Meacham L . Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors. J Natl Cancer Inst. 2019; 112(3):256-265. PMC: 7073918. DOI: 10.1093/jnci/djz108. View

13.

Cardinale D, Iacopo F, Cipolla C . Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020; 7:26. PMC: 7093379. DOI: 10.3389/fcvm.2020.00026. View

14.

Lambrinou E, Decourcey J, Hill L . Personalizing Heart Failure Care to the Patient With Cancer. Curr Heart Fail Rep. 2022; 19(1):1-6. DOI: 10.1007/s11897-021-00536-9. View

15.

Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W . Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol. 2014; 64(13):1310-9. DOI: 10.1016/j.jacc.2014.07.948. View

16.

Lee K, Kang I, Mack W, Mortimer J, Sattler F, Salem G . Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial. BMC Cancer. 2019; 19(1):653. PMC: 6610838. DOI: 10.1186/s12885-019-5887-7. View

17.

Geisberg C, Sawyer D . Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12(6):404-10. PMC: 3999517. DOI: 10.1007/s11906-010-0146-y. View

18.

Leerink J, Verkleij S, Feijen E, Mavinkurve-Groothuis A, Pourier M, Ylanen K . Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review. Heart. 2018; 105(3):210-216. DOI: 10.1136/heartjnl-2018-313634. View

19.

Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick T . Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014; 63(25 Pt A):2751-68. DOI: 10.1016/j.jacc.2014.01.073. View

20.

Thavendiranathan P, Grant A, Negishi T, Plana J, Popovic Z, Marwick T . Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2012; 61(1):77-84. DOI: 10.1016/j.jacc.2012.09.035. View